A new advanced artificial intelligence (AI) algorithm more accurately model how genes associated with specific autoimmune diseases are expressed and regulated and to identify additional genes of risk.

NEWARK, DELAWARE / ACCESS Newswire / February 26, 2026 / The global autoimmune disease testing market is witnessing steady expansion as healthcare systems intensify focus on early diagnosis and ...

Exagen Inc. has reached a major milestone by completing its 1,000,000th AVISE CTD test, a diagnostic tool for autoimmune and connective tissue diseases. This achievement highlights the company’s ...

Exagen Inc. has appointed Dr. Michael Mahler as Chief Scientific Officer, recognizing his extensive expertise in immunology and autoimmune research. Dr. Mahler earned his Ph.D. from the University of ...

Autoimmune rheumatic diseases (ARDs) represent a diverse group of conditions in which the immune system mistakenly targets the body’s own tissues, often affecting the musculoskeletal system and ...

HERSHEY, Pa. — A new advanced artificial intelligence (AI) algorithm may lead to better — and earlier — predictions and novel therapies for autoimmune diseases, which involve the immune system ...